Preparation method and application of rosmarinic acid hydrogel without cross-linking agent
By modifying the method of forming dynamic boric acid ester bonds between carboxymethyl chitosan and rosemary acid in water, the complex preparation of rosemary acid hydrogels and the toxicity of crosslinking agents in the prior art is solved, and the cross-linking agents is achieved The rosemary acid hydrogel preparation of the combination agent has simple, safe and responsive release characteristics, suitable for diabetic wound treatment.
Patent Information
- Application Number
- CN202410937471.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-12
- Publication Date
- 2024-11-01
AI Technical Summary
The existing preparation methods for rosemary acid hydrogels are complex and require the addition of chemical crosslinking agents, which have potential biotoxicity problems.
Carboxymethyl chitosan is modified by 4-formylphenylboric acid to form carboxymethyl chitosan modified with phenylboric acid group, and mixed with rosemary acid in water to form a non-crosslinking through dynamic borate ester bonds Rosemary acid hydrogel agent.
It realizes a simple preparation method without the need to add chemical crosslinking agents, reduces the toxic effect, and has environmentally responsive release of rosemary acid. It is suitable for the treatment of diabetes wounds and has good clinical application value.
Smart Images

Figure CN118873733A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and particularly relates to a preparation method and application of a cross-linking agent-free rosmarinic acid hydrogel. Background Art
[0002] Wound healing is a complex and dynamic process that requires a sophisticated integration of biological and molecular information such as cell migration, cell proliferation, and extracellular matrix deposition. It mainly includes the following important overlapping stages: hemostasis, inflammatory response, migration-proliferation, and tissue remodeling. However, compared with ordinary wounds, the complex microenvironment of diabetic wounds exhibits properties that hinder this process. The intense oxidative stress response at the diabetic wound produces a large amount of ROS, high expression of proinflammatory cytokines, and bacterial infection, which causes wound healing to remain in the persistent inflammatory response stage.
[0003] Rosmarinic acid is a naturally occurring polyphenolic substance that is widely distributed in plants of the Boraginaceae family, such as rosemary, thyme, and salvia. Rosmarinic acid has many excellent biological activities, such as antioxidant, anti-inflammatory, and antibacterial, and has attracted widespread attention in basic research on wound healing.
[0004] Hydrogels are considered to be ideal wound dressings because of their good hydrophilicity, excellent biocompatibility, unique three-dimensional network structure and outstanding drug loading capacity. These excellent structures are conducive to oxygen exchange in the wound, enhance the absorption of wound exudate, maintain a good moist environment, provide a scaffold for cell migration and attachment, and act as a barrier to prevent microorganisms from entering and infecting the wound.
[0005] CN115944774A reports a chitosan and polyvinyl alcohol-based hydrogel loaded with rosmarinic acid, and CN110742859A uses thermosensitive chitosan / sodium glycerophosphate to prepare a hydrogel, and then loads the liposomes encapsulating rosmarinic acid into the hydrogel. In the above patents, rosmarinic acid is only doped or loaded into the hydrogel as a drug to form a rosmarinic acid hydrogel. The preparation method is relatively complicated and requires the addition of a chemical cross-linking agent, which has potential biological toxicity.
[0006] In view of this, there is still a need to develop a hydrogel that does not require a cross-linking agent and is safe and harmless. Summary of the invention
[0007] The purpose of the present invention is to provide a preparation method and application of a cross-linking agent-free rosmarinic acid hydrogel, aiming to solve the problem that the preparation method of rosmarinic acid hydrogel in the prior art is complicated and needs to add a chemical cross-linking agent.
[0008] In order to achieve the above object, the present invention specifically adopts the following technical solutions: The present invention provides a method for preparing a cross-linking agent-free rosmarinic acid hydrogel, comprising: A method for preparing a cross-linking agent-free rosmarinic acid hydrogel, comprising: Carboxymethyl chitosan was modified with 4-formylphenylboronic acid to obtain carboxymethyl chitosan modified with phenylboronic acid groups (PBA-CMCS). Then, the carboxymethyl chitosan modified with phenylboronic acid groups and rosmarinic acid were dissolved in water respectively and then mixed evenly to form a dynamic borate ester bond through the phenylboronic acid bond and the phenolic hydroxyl group of rosmarinic acid, thereby forming a gel.
[0009] Furthermore, the operation method of modifying carboxymethyl chitosan with 4-formylphenylboronic acid is as follows: dissolving carboxymethyl chitosan in deionized water, adding 4-formylphenylboronic acid, reacting at room temperature for 2-12 h, then adding sodium borohydride, stirring and reacting at room temperature for 12-24 h, dialyzing the reaction product in deionized water and then freeze-drying to obtain carboxymethyl chitosan modified with phenylboronic acid groups.
[0010] Furthermore, the molecular weight of the carboxymethyl chitosan is 100-200 kDa; the molar ratio of carboxymethyl chitosan, 4-formylphenylboric acid and sodium borohydride is 1:(0.5-3):(0.5-3); the dialysis molecular weight cutoff is 8-14 kDa, and the dialysis time is 2-7 days.
[0011] Furthermore, the mass concentration of carboxymethyl chitosan modified by phenylboronic acid groups after being dissolved in water is 2%-6%, and the mass concentration of rosmarinic acid after being dissolved in water is 1%-5%.
[0012] Furthermore, the molar ratio of the carboxymethyl chitosan modified with phenylboronic acid groups to rosmarinic acid is 1:(0.5-3).
[0013] The present invention also provides application of the rosmarinic acid hydrogel in preparing wound dressings for diabetic wounds.
[0014] Compared with the prior art, the present invention has the following beneficial effects: (1) In the preparation process of the rosmarinic acid hydrogel of the present invention, no chemical cross-linking agent needs to be added, which greatly reduces the toxic effects caused by the chemical cross-linking agent.
[0015] (2) The preparation method of the rosmarinic acid hydrogel of the present invention is simple, the reaction conditions are mild, and the content of rosmarinic acid is adjustable.
[0016] (3) The rosmarinic acid hydrogel prepared by the present invention is environmentally responsive and can responsively release rosmarinic acid. It can be used in the treatment of diabetic wounds and has great clinical application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1This is an optical photograph of the formation of rosmarinic acid hydrogel in Example 1 of the present invention.
[0018] Figure 2 These are optical photographs for verifying the adhesion and self-healing properties of the rosmarinic acid hydrogel in Example 1 of the present invention.
[0019] Figure 3 This is a frequency scanning image of the rosmarinic acid hydrogel of Examples 1-3 of the present invention.
[0020] Figure 4 These are continuous alternating transition strain scanning images of the rosmarinic acid hydrogels of Examples 1-3 of the present invention.
[0021] Figure 5 These are optical photographs of the degradation of rosmarinic acid hydrogel in Example 3 of the present invention in different solutions.
[0022] Figure 6 The release rate of rosmarinic acid from the rosmarinic acid hydrogel of Example 3 of the present invention in different environments.
[0023] Figure 7 The scavenging rates of DPPH, O2•− and •OH of carboxymethyl chitosan, rosmarinic acid and rosmarinic acid hydrogel in Example 3 of the present invention are shown.
[0024] Figure 8 The rosmarinic acid hydrogel of Example 3 of the present invention and the commercial excipient Tegaderm TM Optical photographs of diabetic wounds in treated mice. DETAILED DESCRIPTION
[0025] In order to make the purpose, technical scheme and advantages of the present invention clearer, the technical scheme of the present invention will be clearly and completely described below in conjunction with the embodiments. If the specific conditions are not specified in the embodiments, they are carried out according to the conventional conditions or the conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments is not specified, they are all conventional products that can be purchased commercially.
[0026] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.
[0027] Example 1 1) Preparation of phenylborated carboxymethyl chitosan Weigh 1218.9 mg of carboxymethyl chitosan, dissolve it in 100 mL of deionized water, add 450 mg of 4-formylphenylboronic acid, react for 2 h, then add 113 mg of sodium borohydride, stir at room temperature, and react overnight. After the reaction is completed, dialyze it in deionized water for 3 days using an 8-14 kDa dialysis bag, change the water 3-4 times a day, and freeze-dry it after dialysis purification to obtain phenylboronic acid carboxymethyl chitosan.
[0028] 2) Preparation of rosmarinic acid hydrogel Prepare a 28 mg / mL phenylboronic acid-modified carboxymethyl chitosan aqueous solution and a 36 mg / mL rosmarinic acid aqueous solution; mix the two in a liquid volume ratio of 2:1 and stir at room temperature to obtain a rosmarinic acid hydrogel.
[0029] Figure 1 , Figure 2 These are optical photographs showing the formation, adhesion and self-healing properties of the rosmarinic acid hydrogel prepared in this example.
[0030] Example 2 1) Preparation of phenylborated carboxymethyl chitosan Weigh 1218.9 mg of carboxymethyl chitosan, dissolve it in 100 mL of deionized water, add 600 mg of 4-formylphenylboronic acid, react for 2 h, then add 152 mg of sodium borohydride, stir at room temperature, and react overnight. After the reaction is completed, dialyze it in deionized water for 3 days using an 8-14 kDa dialysis bag, change the water 3-4 times a day, and freeze-dry it after dialysis purification to obtain phenylboronic acid carboxymethyl chitosan.
[0031] 2) Preparation of rosmarinic acid hydrogel Prepare a 42 mg / mL phenylboronic acid-modified carboxymethyl chitosan aqueous solution and a 36 mg / mL rosmarinic acid aqueous solution; mix the two in a liquid volume ratio of 2:1, and stir at room temperature to obtain a rosmarinic acid hydrogel.
[0032] Example 3 1) Preparation of phenylborated carboxymethyl chitosan Weigh 1218.9 mg of carboxymethyl chitosan, dissolve it in 100 mL of deionized water, add 750 mg of 4-formylphenylboronic acid, react for 2 h, then add 190 mg of sodium borohydride, stir at room temperature, and react overnight. After the reaction is completed, dialyze it in deionized water for 3 days using an 8-14 kDa dialysis bag, change the water 3-4 times a day, and freeze-dry it after dialysis purification to obtain phenylboronic acid carboxymethyl chitosan.
[0033] 2) Preparation of rosmarinic acid hydrogel Prepare a 56 mg / mL phenylboronic acid-modified carboxymethyl chitosan aqueous solution and a 36 mg / mL rosmarinic acid aqueous solution; mix the two in a liquid volume ratio of 2:1, and stir at room temperature to obtain a rosmarinic acid hydrogel.
[0034] Figure 3 The frequency scanning images of rosmarinic acid hydrogels of Examples 1-3 of the present invention. In the figure, RAgel 1 is Example 1, RAgel 2 is Example 2, and RAgel 3 is Example 3. It can be seen from the figure that within the test frequency range of 0.1-100 rad / s, the storage modulus (G') of RAgel is greater than its loss modulus (G"), indicating that RAgel is in a gel state and maintains its good elastic characteristics. In addition, the storage modulus of the hydrogel is concentration-dependent with PBA-CMCS. The higher the concentration of PBA-CMCS, the greater the storage modulus of the hydrogel of the corresponding component.
[0035] Figure 4 The continuous alternating transition strain scanning image of the rosmarinic acid hydrogel of Example 1-3 of the present invention. It can be seen from the figure that at low strain (1%), the G' of the hydrogel is significantly greater than G", showing a gel state, and when the strain reaches 1000%, the G' of the hydrogel is lower than G", showing a sol state. When the strain is restored to 1%, the storage modulus of the hydrogel increases rapidly and returns to the gel state, indicating that RAgel has good self-healing properties.
[0036] Figure 5 These are optical photographs of the degradation of rosmarinic acid hydrogel in Example 3 of the present invention in different solutions. It can be seen intuitively that the rosmarinic acid hydrogel is relatively stable in PBS, but is easily degraded in the environment of glucose and hydrogen peroxide.
[0037] Figure 6 The release rate of rosmarinic acid in different environments of the rosmarinic acid hydrogel of Example 3 of the present invention is: Figure 6 The results showed that rosmarinic acid hydrogel could responsively release rosmarinic acid in the environment of glucose and hydrogen peroxide.
[0038] Figure 7 The scavenging rates of DPPH, O2•− and •OH of carboxymethyl chitosan, rosmarinic acid and rosmarinic acid hydrogel in Example 3 of the present invention are shown. The results show that rosmarinic acid hydrogel has little effect on the antioxidant properties of rosmarinic acid itself.
[0039] Figure 8 The rosmarinic acid hydrogel of Example 3 of the present invention and the commercial excipient Tegaderm TM Optical photos of diabetic wounds in mice show that the wound healing effect of rosmarinic acid hydrogel is better than that of commercial excipients such as Tegaderm. TM .
[0040] The embodiments described above only express several preferred embodiments of the present invention, and the descriptions thereof are relatively specific and detailed, but are not intended to limit the present invention. It should be noted that for those skilled in the art, the present invention may also have various changes and modifications, and any modifications, equivalent substitutions, improvements, etc. made within the concept and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A method for preparing a cross-linking agent-free rosmarinic acid hydrogel, characterized in that: include: Carboxymethyl chitosan is modified with 4-formylphenylboronic acid to obtain carboxymethyl chitosan modified with phenylboronic acid groups; then the carboxymethyl chitosan modified with phenylboronic acid groups and rosmarinic acid are dissolved in water respectively, and then mixed evenly, and dynamic borate ester bonds are formed through phenylboronic acid bonds and phenolic hydroxyl groups of rosmarinic acid to form a gel.
2. The method for preparing the crosslinking agent-free rosmarinic acid hydrogel according to claim 1, characterized in that: The operation method of modifying carboxymethyl chitosan with 4-formylphenylboronic acid is as follows: dissolving carboxymethyl chitosan in deionized water, adding 4-formylphenylboronic acid, reacting at room temperature for 2-12 h, then adding sodium borohydride, stirring and reacting at room temperature for 12-24 h, dialyzing the reaction product in deionized water and freeze-drying to obtain carboxymethyl chitosan modified with phenylboronic acid groups.
3. The method for preparing the crosslinking agent-free rosmarinic acid hydrogel according to claim 2, characterized in that: The molecular weight of the carboxymethyl chitosan is 100-200 kDa; the molar ratio of the carboxymethyl chitosan, 4-formylphenylboronic acid and sodium borohydride is 1:(0.5-3):(0.5-3); the molecular weight cutoff of the dialysis is 8-14 kDa, and the dialysis time is 2-7 days.
4. The method for preparing the cross-linking agent-free rosmarinic acid hydrogel according to claim 1, characterized in that: The mass concentration of carboxymethyl chitosan modified by phenylboronic acid groups after dissolving in water is 2%-6%, and the mass concentration of rosmarinic acid after dissolving in water is 1%-5%.
5. The method for preparing the cross-linking agent-free rosmarinic acid hydrogel according to claim 1, characterized in that: The molar ratio of the carboxymethyl chitosan modified with phenylboronic acid groups to rosmarinic acid is 1:(0.5-3).
6. The rosmarinic acid hydrogel obtained by the preparation method according to any one of claims 1 to 5.
7. Use of the rosmarinic acid hydrogel as claimed in claim 6 in preparing a wound dressing for a diabetic wound.
Citation Information
Cited By
Preparation and application of injectable hydrogel for repairing infectious bone defects
CN118320178A
Preparation and use of an injectable hydrogel for repairing infected bone defects
CN118320178B
